Read more about the article ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy
Read more about the article Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Read more about the article Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy
Read more about the article Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Read more about the article Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)